TD Cowen lowered the firm’s price target on LifeStance to $7 from $8.50 and keeps a Hold rating on the shares. The firm said margins will compress into 2H from a combination of lower TRPV and increased hiring activity. Despite the positive outlook and recent performance valuation remains elevated relative to the firm’s growth universe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance sees Q3 revenue $290M-$310M, consensus $301.9M
- LifeStance raises 2024 revenue view to $1.2B-$1.242B from $1.19B-$1.24B
- LifeStance reports Q2 EPS (6c), consensus (7c)
- LifeStance to Host Second Quarter 2024 Earnings Conference Call on August 8, 2024
- LifeStance Health Group Finalizes Executive Separation Terms